rheumatoid arthritis
Rheumatoid arthritis trials now operate in a treat-to-target paradigm where clinical remission (DAS28 < 2.6) is the primary goal, and biologics failure triggers a logical sequence of mechanism switching. The JAK inhibitor class (tofacitinib, baricitinib, upadacitinib) has added an oral option after TNF/IL-6 inhibitor failure, though cardiovascular safety signals have reshaped prescribing guidance.
Active trials evaluate next-generation JAK inhibitors with improved selectivity, IL-17A/F bispecifics, TYK2 inhibitors, CAR-T cell therapy for refractory disease, and precision medicine biomarkers (MBDA score, synovial biopsy) to guide treatment selection. Tapering and de-escalation in sustained remission is a growing research priority.
Disease Burden & Epidemiology
Rheumatoid arthritis (RA) is the most common inflammatory arthritis, affecting approximately 18 million people globally, with a prevalence of 0.5–1% in developed countries. In the United States, the CDC estimates approximately 1.5 million adults live with RA. The condition is 2–3 times more common in women than men and typically presents between ages 30 and 60, though it can occur at any age including childhood (juvenile idiopathic arthritis). RA is an autoimmune disease in which the immune system mistakenly attacks the synovial lining of joints, causing progressive inflammation, cartilage destruction, and bone erosion. Without adequate treatment, approximately 50% of patients develop significant functional disability within 10 years of diagnosis. Beyond joints, RA is associated with substantially elevated cardiovascular risk — patients have a 1.5–2-fold greater risk of myocardial infarction and stroke — and with lung disease, secondary Sjögren's syndrome, and increased malignancy risk. The annual direct and indirect economic cost of RA in the US exceeds $39 billion. Early, aggressive treatment with disease-modifying therapies has dramatically improved outcomes, and current trials target sustained remission, drug-free remission, and cardiovascular risk reduction alongside joint protection.
Key Research Trends & Landmark Studies
The ORAL Surveillance trial was a landmark comparative safety study demonstrating that tofacitinib (a JAK inhibitor) carried a higher risk of major adverse cardiovascular events and malignancy versus TNF inhibitors in patients over 50 with cardiovascular risk factors β€” a result that prompted FDA label updates and prescribing restrictions for the entire JAK inhibitor class in RA. The SELECT-COMPARE trial established upadacitinib as more efficacious than adalimumab in patients with inadequate methotrexate response, using ACR50 and low disease activity as primary endpoints. The RA-BEAM trial showed baricitinib superiority over adalimumab at 12 weeks in DMARD-inadequate responders. For refractory disease, the pioneering CAR-T case series (Schett group, Erlangen) demonstrated drug-free remission of months to years in treatment-refractory RA patients, driving formal Phase 1/2 trials of CD19-targeted CAR-T in RA and other autoimmune diseases. The TICOPA trial validated the treat-to-target paradigm in psoriatic arthritis (applying RA methodology), and tapering protocols following the PRIZE and POET trials are defining evidence-based approaches to biologic dose reduction in sustained remission.
Patient Guide: How to Find & Join a Trial
Patients with rheumatoid arthritis at any treatment stage β€” from newly diagnosed to refractory to multiple biologics β€” may qualify for clinical trials. For trials in newly diagnosed or biologic-naive patients, your baseline DAS28 score (a composite of joint counts, inflammatory markers, and patient global assessment), current DMARD regimen, and duration of disease since diagnosis are the key eligibility parameters. For trials in treatment-refractory patients, documentation of prior biologic and targeted synthetic DMARD failures (including drug names, durations, doses, and reasons for discontinuation) is essential screening documentation. Most RA trials are conducted at academic rheumatology programs at university hospitals; however, community rheumatologists increasingly participate in multi-site industry-sponsored trials. Patients interested in the most experimental approaches β€” including CAR-T cell therapy for refractory RA β€” should contact academic centers in Germany (Erlangen, Dresden) or US programs at UCSF, NYU, or Penn that have initiated formal clinical programs.